| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA598603
Max Phase: Preclinical
Molecular Formula: C34H36N2O3
Molecular Weight: 520.67
Molecule Type: Small molecule
Associated Items:
Representations
Canonical SMILES: COc1ccc(C(c2ccc(OC)cc2)N2CCN(C(=O)CC(c3ccccc3)c3ccccc3)CC2)cc1
Standard InChI: InChI=1S/C34H36N2O3/c1-38-30-17-13-28(14-18-30)34(29-15-19-31(39-2)20-16-29)36-23-21-35(22-24-36)33(37)25-32(26-9-5-3-6-10-26)27-11-7-4-8-12-27/h3-20,32,34H,21-25H2,1-2H3
Standard InChI Key: CBDZLOJIUYHCHO-UHFFFAOYSA-N
Associated Targets(Human)
CACNA2D1 Tclin Voltage-dependent L-type calcium channel alpha1C/alpha2delta/beta1b (64 Activities)
CACNA2D1 Tclin N-type calcium channel alpha-1b/alpha2delta-1/beta-1b (50 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
CACNA1G Tclin Voltage-gated T-type calcium channel alpha-1G subunit (1361 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Associated Targets(non-human)
Cacna1b Voltage-gated N-type calcium channel alpha-1B subunit (471 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 520.67 | Molecular Weight (Monoisotopic): 520.2726 | AlogP: 6.16 | #Rotatable Bonds: 9 |
| Polar Surface Area: 42.01 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 0 |
| #RO5 Violations: 2 | HBA (Lipinski): 5 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 2 |
| CX Acidic pKa: | CX Basic pKa: 6.54 | CX LogP: 6.16 | CX LogD: 6.10 |
| Aromatic Rings: 4 | Heavy Atoms: 39 | QED Weighted: 0.27 | Np Likeness Score: -0.72 |
References
| 1. Pajouhesh H, Feng ZP, Ding Y, Zhang L, Pajouhesh H, Morrison JL, Belardetti F, Tringham E, Simonson E, Vanderah TW, Porreca F, Zamponi GW, Mitscher LA, Snutch TP.. (2010) Structure-activity relationships of diphenylpiperazine N-type calcium channel inhibitors., 20 (4): [PMID:20117000] [10.1016/j.bmcl.2010.01.008] |
| 2. (2004) Calcium channel inhibitors comprising benzhydril spaced from piperazine, |
Source
Source(2):